Skip Navigation

Annals of Oncology 2004 15(10):1467-1475; doi:10.1093/annonc/mdh392
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Savage, K. J.
Right arrow Articles by Connors, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savage, K. J.
Right arrow Articles by Connors, J. M.
Related Collections
Right arrow 2004 - Editors Choice
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Original Article

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

K. J. Savage1,*, M. Chhanabhai2, R. D. Gascoyne2 and J. M. Connors1

Divisions of 1Medical Oncology and 2 Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada

* Correspondence to: Dr Kerry J. Savage, B.C. Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. Tel: +1-604-877-6000; Fax: +1-604-877-0585; Email: ksavage{at}bccancer.bc.ca

Background: All peripheral T-cell lymphomas (PTCLs) diagnosed at a single institution were evaluated to determine the unique clinical features and outcome of specific entities and test the predictive validity of the International Prognostic Index (IPI).

Patients and methods: Cases of PTCL seen at the British Columbia Cancer Agency between 1981 and 2000 were identified. Pathologic material was re-assessed and classified according to the WHO classification, and patients were staged and treated uniformly according to era-specific guidelines. In total, there were 199 patients with PTCL and the most common subtypes were peripheral T-cell lymphoma unspecified (PTCL-US) (59%), anaplastic large-cell lymphoma, systemic type (ALCL) (17%) and extranodal NK/T-cell lymphoma, nasal and nasal-type (NASAL) (9%). Most patients were treated with CHOP-type chemotherapy.

Results: Three distinct prognostic subgroups were notable on survival analysis: favorable (cutaneous ALCL), 5-year overall survival (OS) 78%; intermediate [PTCL, ALCL and angioimmunoblastic lymphoma (AILT)], 5-year OS 35–43%; unfavorable [NASAL and enteropathy-type T-cell lymphoma (ETTL)], 5-year OS 22–24%. Furthermore, in PTCL-US and ALCL clinical separation of patients into good risk (IPI 0,1) and poor risk (IPI ≥2) subsets was demonstrated.

Conclusions: A large proportion of PTCL patients have poor risk disease and/or a histologically aggressive subtype with frequent relapse and unfavorable outcome. For these patients, treatment with CHOP chemotherapy is only minimally effective and new strategies need to be developed, an effort that will require a multi-institution international collaboration due to the rarity of most subtypes.

Key words: peripheral, T-cell lymphomas, WHO classification, IPI


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al.
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al.
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
Ann. Onc., May 1, 2008; 19(5): 958 - 963.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. J. Alekshun, D. Rezania, E. Ayala, H. Cualing, and L. Sokol
Skeletal Muscle Peripheral T-Cell Lymphoma
J. Clin. Oncol., January 20, 2008; 26(3): 501 - 503.
[Full Text] [PDF]


Home page
BloodHome page
T. R. Halfdanarson, M. R. Litzow, and J. A. Murray
Hematologic manifestations of celiac disease
Blood, January 15, 2007; 109(2): 412 - 421.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al.
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Blood, December 15, 2006; 108(13): 4163 - 4169.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al.
Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score
J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al.
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma
J. Clin. Oncol., January 1, 2006; 24(1): 181 - 189.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
E. S. Jaffe
Pathobiology of Peripheral T-cell Lymphomas
Hematology, January 1, 2006; 2006(1): 317 - 322.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. P. Greer
Therapy of Peripheral T/NK Neoplasms
Hematology, January 1, 2006; 2006(1): 331 - 337.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology, January 1, 2005; 2005(1): 267 - 277.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. O. Armitage, J. M. Vose, and D. D. Weisenburger
Towards understanding the peripheral T-cell lymphomas
Ann. Onc., October 1, 2004; 15(10): 1447 - 1449.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.